Norway produces around half of the world's farmed Atlantic salmon β a position it has held for decades. The salmon price cycle drives earnings for Mowi, SalMar, Grieg Seafood and LerΓΈy β all listed on Oslo BΓΈrs.
Salmon prices move in 3-5 year cycles driven by supply growth (biological constraints limit how fast Norway can grow production) and demand growth (Asia particularly). BUY below NOK 42/kg β salmon farming unprofitable, stocks cheap. SELL above NOK 82/kg β salmon farming highly profitable, stocks expensive. Current salmon price: NOK 95/kg β above SELL threshold.
Mowi (largest), SalMar, Grieg Seafood, LerΓΈy Seafood and Austevoll Seafood all trade on Oslo BΓΈrs. At NOK 95/kg, all are generating strong earnings β but the Signycle signal says SELL, not BUY.
What makes salmon farming unique among cyclical industries is that supply is constrained by biology, not just by capital. A salmon takes roughly two to three years to grow from smolt to harvest weight, and there is a hard limit to how fast Norway can expand production: licensing is tightly regulated, suitable fjord locations are finite, and the industry has largely reached the biological limits of conventional net-pen farming. This means supply cannot respond quickly to high prices the way it can in, say, shipping or mining β which gives the salmon cycle its distinctive, slow-turning character.
For an investor, this is the crucial insight: when salmon prices are high, producers cannot simply flood the market with new fish next quarter. The biological lag means elevated prices can persist longer than in faster-cycling commodities β but it also means that when a supply wave finally does arrive (a strong smolt year-class reaching harvest), it weighs on prices for an extended period. Reading the salmon cycle is about anticipating these multi-year biological waves, not quarterly earnings.
Salmon farming carries category-specific risks that don't exist in other cyclical sectors, and they can override the price cycle entirely. Sea lice and disease outbreaks can force early harvests or cull entire pens, hitting volumes regardless of where prices sit. Biological mortality β from algal blooms, temperature spikes, or disease β directly reduces harvestable tonnage. And regulation looms large: Norway's proposed and implemented resource rent taxation on the sector has been one of the biggest swing factors for the listed names in recent years, capable of moving share prices independently of the salmon price itself.
This is why a salmon investor cannot rely on the price signal alone. A SELL signal on salmon prices tells you the demand-supply balance is stretched, but the biological and regulatory overlay means individual producers can diverge sharply from the headline cycle depending on their fish health, geographic exposure, and tax position.
Unlike iron ore or crude oil, salmon demand has a powerful structural growth story underneath the cycle. Global appetite for farmed salmon β particularly in Asia and North America β has grown steadily as a premium, healthy protein, and that demand growth tends to put a rising floor under prices over time. This is what separates salmon from a pure commodity cycle: the long-term trend is upward-sloping, even as prices swing through multi-year cycles around that trend.
For investors, this means salmon rewards a different mindset than most cyclicals. The biological supply ceiling plus structural demand growth means the cyclical lows have historically been buying opportunities within a secular uptrend β provided you can stomach the volatility and the biological risk. The key, as always, is entering when the cycle signal is favourable rather than when the headlines about record earnings are loudest.
The bottom line: Norwegian salmon is a biological cycle layered on a structural growth story, with risks β disease, lice, taxation β that no price chart fully captures. Use the live salmon price signal below to see where the cycle sits, but weigh it against the biological and regulatory picture for each producer.